Neumora Therapeutics’ head of R&D sells over $490k in company stock, a move that has sent ripples through the pharmaceutical industry. This significant transaction raises questions about the company’s future prospects, the potential impact on investor sentiment, and the broader implications for research and development activities. The sale, which was …
Read More »
Privacy Overview
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.